Brokerages Set Agenus Inc. (NASDAQ:AGEN) Price Target at $10.00

Agenus Inc. (NASDAQ:AGEN) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $10.00.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research report on Wednesday, January 22nd.

Agenus Price Performance

Shares of AGEN opened at $2.35 on Friday. The business’s 50 day moving average is $3.28 and its two-hundred day moving average is $3.94. Agenus has a 52-week low of $2.31 and a 52-week high of $19.69. The firm has a market cap of $55.13 million, a price-to-earnings ratio of -0.21 and a beta of 1.23.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently made changes to their positions in the company. EP Wealth Advisors LLC acquired a new stake in shares of Agenus during the 3rd quarter valued at approximately $55,000. Corton Capital Inc. acquired a new stake in shares of Agenus during the 4th quarter valued at approximately $36,000. Point72 DIFC Ltd raised its position in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 11,542 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Agenus during the 4th quarter valued at approximately $51,000. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Agenus during the 4th quarter valued at approximately $55,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.